Why carry out the study?

Patients' preference and quality of life are important in deciding the treatment strategy for patients with type 2 diabetes mellitus.

This study aimed to assess the effect of omarigliptin on patients’ psychological attitudes and responses compared with daily dipeptidyl peptidase-4 inhibitors (DPP4is) by measuring the burden of pharmacotherapy using the Diabetic Treatment Burden Questionnaire (DTBQ).

What was learned from the study?

Although the change in the DTBQ total score did not differ between the groups that switched to omarigliptin and the group that continued daily DPP4is, the DTBQ subscale scores, implementation and flexibility burden scores significantly decreased in the group that switched to omarigliptin.

The results in this study may suggest the possibility of switching from daily DPP4is to omarigliptin to decrease the patients’ medication burden.